Your browser is no longer supported. Please, upgrade your browser.
ENTX Entera Bio Ltd. daily Stock Chart
Entera Bio Ltd.
Index- P/E- EPS (ttm)-0.92 Insider Own36.01% Shs Outstand11.43M Perf Week0.95%
Market Cap60.58M Forward P/E- EPS next Y-1.16 Insider Trans- Shs Float7.31M Perf Month-5.69%
Income-10.00M PEG- EPS next Q-0.09 Inst Own6.70% Short Float0.04% Perf Quarter1.15%
Sales- P/S- EPS this Y-877.90% Inst Trans5.95% Short Ratio0.65 Perf Half Y-
Book/sh-2.95 P/B- EPS next Y- ROA- Target Price12.00 Perf Year-
Cash/sh0.57 P/C9.32 EPS next 5Y- ROE- 52W Range4.11 - 7.60 Perf YTD-15.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.26% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low28.95% ATR0.51
Employees19 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)49.19 Volatility10.03% 8.81%
OptionableNo Debt/Eq- EPS Q/Q172.50% Profit Margin- Rel Volume0.39 Prev Close5.30
ShortableYes LT Debt/Eq- EarningsNov 19 AMC Payout- Avg Volume4.04K Price5.30
Recom2.00 SMA20-2.33% SMA50-1.90% SMA200-3.67% Volume0 Change0.00%
Nov-08-18 08:00AM  Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism GlobeNewswire -7.89%
Oct-02-18 08:00AM  Entera Bio Appoints Two New External Independent Members to the Board of Directors GlobeNewswire +12.65%
Sep-21-18 09:15AM  Entera Bio Appoints Dr. Arthur Santora as Chief Medical Officer GlobeNewswire
Aug-20-18 04:05PM  Entera Bio Reports Second Quarter 2018 Financial Results and Operating Update GlobeNewswire
Aug-09-18 12:00PM  Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors GlobeNewswire
Aug-01-18 08:00AM  Entera Bio Completes Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients GlobeNewswire +7.34%
Jul-02-18 04:05PM  Entera Bio Ltd. Announces Closing of Initial Public Offering GlobeNewswire +5.56%
Jun-28-18 08:53AM  Entera Bio Ltd. Announces Pricing of Initial Public Offering GlobeNewswire
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.